The National Medical Products Administration (NMPA) has granted regulatory approval to US-based pharmaceutical major Bristol-Myers Squibb (BMS, NYSE: BMY) for its first-in-class selective tyrosine kinase 2 (TYK2) inhibitor, Sotyktu (deucravacitinib). The drug is indicated for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Mechanism of Action and Previous Approval
Deucravacitinib, which was first approved for marketing in the US in September 2022, selectively targets TYK2 through a unique “allosteric inhibition” mechanism. This approach inhibits the signaling of IL-23, IL-12, and type I interferon (IFN) without affecting JAK1, JAK2, and JAK3 at therapeutic doses.
Global Clinical Development
Deucravacitinib is currently being assessed in multiple clinical studies worldwide, exploring its potential in treating various conditions such as psoriasis, psoriatic arthritis, and systemic lupus erythematosus. This broad clinical development program underscores Bristol Myers Squibb’s commitment to advancing innovative treatments for immune-mediated diseases.-Fineline Info & Tech
